molmir

molmir Inc. is a Japanese biotech startup spun out of Nara Medical University, AIST, and Tokushima University, developing novel drug discovery platform technologies based on the observation of molecular dynamics at the atomic level. The company's core innovation is a 'chemical tongue' sensing technology that detects phase separation — a phenomenon in living cells — enabling it to capture the movement and interaction of molecules that constantly change shape and were previously undruggable by conventional methods. This platform is being applied to research into treatments for ALS, Alzheimer's disease, cancer, and heart disease. Founded in 2022 and headquartered in Nara, Japan, molmir has received multiple grants, won the Deep Tech Venture of the Year 2025 award, and entered strategic R&D collaborations with partners including OrganoTherapeutics.